<DOC>
	<DOCNO>NCT01919554</DOCNO>
	<brief_summary>The purpose study investigate safety tolerability different dos sublingual tablet house dust mite ( HDM ) allergen extract adolescent house dust mite-associated allergic rhinitis .</brief_summary>
	<brief_title>Safety Study Sublingual Immunotherapy Tablets House Dust Mite Allergen Extracts Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Written inform consent patient parent ( ) /legal representative . Male female patient 12 17 year . Diagnosed rhinitis medical history consistent HDMinduced allergic rhinitis least 1 year visit 1 Positive Skin Prick Test House Dust Mites ( HDM ) HDMspecific IgE serum value â‰¥ 0.7 kUnit/L . Concommittant control asthma allow GINA 1 2 treatment step Spirometry best FEV1 &gt; 80 % predict FEV1 . Patient nasal oral disease could interfere safety assessment Patient undergone recent nasal surgery Patient asthma receive therapy consistent GINA ( Global INitiative Asthama ) treatment step 3 , 4 , 5 . Patient partially control uncontrolled asthma Patient past current disease , judge Investigator , may affect patient 's participation outcome study . Female patient pregnant breastfeeding/lactating . Female patient childbearing potential planning pregnancy trial use medically accept contraceptive method . Patient treat betablockers , tricyclic antidepressant monoamine oxidase inhibitor ( MAOIs ) . Patient receive allergy specific immunotherapy house dust mites 1 month 5 year screen currently receive immunotherapy allergen . patient history anaphylaxis patient participate clinical study within 12 week visit 1</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>House Dust Mite Allergic Rhinitis</keyword>
	<keyword>Phase I</keyword>
	<keyword>House Dust Mite Allergen Extract</keyword>
</DOC>